DalsnaFinance Account

Kenvue $KVUE

Consumer Staples · Personal Care Products · NYSE/NASDAQ

S&P 500 Russell 1000 New Jersey

Create a scorecard

$18.67

+0.66 (+3.66%)

As of Oct 15, 2026, 10:06 PM EDT

Price history

Loading chart…

Kenvue (KVUE) is trading up at $18.67 (+3.66%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Consumer Staples sector.

IPO: May 4, 2023 · $22.00 offering · NYSE · View IPO details →

Kenvue revenue & net income history (FY2021–FY2025)

RevenueNet incomeNet margin (right axis, %)

Kenvue annual financial statements
	FY2021Jan 2022	FY2022Jan 2023	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	$15.1B	$14.9B	$15.4B	$15.5B	$15.1B
Growth (year over year)	—	−0.7%	+3.3%	+0.1%	−2.1%
Gross profit	$8.42B	$8.29B	$8.64B	$8.96B	$8.79B
Gross margin	55.9%	55.4%	56.0%	58.0%	58.1%
Operating income	$2.92B	$2.67B	$2.51B	$1.84B	$2.41B
Operating margin	19.4%	17.9%	16.3%	11.9%	16.0%
Net income	$2.08B	$2.06B	$1.66B	$1.03B	$1.47B
Net margin	13.8%	13.8%	10.8%	6.7%	9.7%
EPS (diluted)	$1.21	$1.20	$0.90	$0.54	$0.76
Balance sheet
Cash and equivalents	$740.0M	$1.23B	$1.38B	$1.07B	$1.06B
Total assets	—	$27.3B	$27.9B	$25.6B	$27.1B
Total liabilities	—	$7.35B	$16.6B	$15.9B	$16.3B
Long-term debt	—	$0	$7.69B	—	—
Shareholders' equity	$20.5B	$20.0B	$11.2B	$9.67B	$10.8B
Cash flow
Operating cash flow	$334.0M	$2.52B	$3.17B	$1.77B	$2.20B
Capital expenditure	$295.0M	$375.0M	$469.0M	$434.0M	$475.0M
Free cash flow	$39.0M	$2.15B	$2.70B	$1.33B	$1.72B
Dividends paid	$0	$0	$766.0M	$1.55B	$1.58B
Share buybacks	—	$0	$7.00M	$235.0M	$197.0M

RevenueNet incomeNet margin (right axis, %)

Kenvue quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Income statement
Revenue	$3.90B	$3.66B	$3.74B	$3.84B	$3.76B	$3.78B	$3.91B	$3.96B
Growth (year over year)	−0.4%	−0.1%	−3.9%	−4.0%	−3.5%	+3.2%	+4.5%	+3.0%
Gross profit	$2.28B	$2.07B	$2.17B	$2.26B	$2.23B	$2.14B	$2.30B	$2.30B
Gross margin	58.5%	56.5%	58.0%	58.9%	59.1%	56.5%	58.9%	58.2%
Operating income	$654.0M	$483.0M	$558.0M	$692.0M	$629.0M	$535.0M	$767.0M	$699.0M
Operating margin	16.8%	13.2%	14.9%	18.0%	16.7%	14.2%	19.6%	17.7%
Net income	$383.0M	$293.0M	$322.0M	$420.0M	$398.0M	$330.0M	$474.0M	$456.0M
Net margin	9.8%	8.0%	8.6%	10.9%	10.6%	8.7%	12.1%	11.5%
EPS (diluted)	$0.20	$0.16	$0.17	$0.22	$0.21	$0.16	$0.25	$0.24
Balance sheet
Cash and equivalents	$1.06B	$1.07B	$1.06B	$1.07B	$1.14B	$1.06B	$1.07B	$1.11B
Total assets	$26.9B	$25.6B	$26.3B	$27.1B	$27.2B	$27.1B	$26.9B	$26.7B
Total liabilities	$16.3B	$15.9B	$16.2B	$16.4B	$16.6B	$16.3B	$16.2B	$16.2B
Shareholders' equity	$10.6B	$9.67B	$10.1B	$10.7B	$10.6B	$10.8B	$10.6B	$10.6B
Cash flow
Operating cash flow	$249.0M	$793.0M	$428.0M	$621.0M	$294.0M	$854.0M	$489.0M	$688.0M
Capital expenditure	$59.0M	$132.0M	$179.0M	$88.0M	$98.0M	$110.0M	$139.0M	$64.0M
Free cash flow	$190.0M	$661.0M	$249.0M	$533.0M	$196.0M	$744.0M	$350.0M	$624.0M
Dividends paid	$393.0M	$393.0M	$392.0M	$393.0M	$398.0M	$398.0M	$398.0M	$398.0M
Share buybacks	$23.0M	$121.0M	$63.0M	$64.0M	$70.0M	$0	$0	$0

From Kenvue's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Kenvue

Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.

Source: Wikipedia — Kenvue